Price (delayed)
$2.67
Market cap
$494.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.03
Enterprise value
$952.79M
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make
There are no recent dividends present for ESPR.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.